



LAWRENCE
LIVERMORE
NATIONAL
LABORATORY

Dynamics of human adipose lipid turnover in health and metabolic disease

P. Arner, S. Bernard, M. Salehpour, G. Possnert, J. Leibl, P. Steier, B. A. Buchholz, M. Eriksson, E. Arner, H. Hauner, T. Skurk, M. Ryden, K. Frayn, K. L. Spalding

July 28, 2011

Nature

Disclaimer

This document was prepared as an account of work sponsored by an agency of the United States government. Neither the United States government nor Lawrence Livermore National Security, LLC, nor any of their employees makes any warranty, expressed or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States government or Lawrence Livermore National Security, LLC. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States government or Lawrence Livermore National Security, LLC, and shall not be used for advertising or product endorsement purposes.

Dynamics of human adipose lipid turnover in health and metabolic disease

Peter Arner^{1, *}, Samuel Bernard², Mehran Salehpour³, Göran Possnert³, Jakob Liebl⁴, Peter Steier⁴, Bruce A. Buchholz⁵, Mats Eriksson¹, Erik Arner⁶, Hans Hauner⁷, Thomas Skurk⁷, Mikael Rydén¹, Keith N. Frayn⁸, Kirsty L. Spalding^{9, *}.

¹Department of Medicine, Karolinska University Hospital, SE-141 86 Stockholm, Sweden.

²Institut Camille Jordan, CNRS UMR 5208, University of Lyon, F-69622 Villeurbanne,

France. ³Department of Physics and Astronomy, Ion Physics, Uppsala University, SE-751 20,

Sweden. ⁴University of Vienna, Faculty of Physics – Isotope Research, Vienna, Austria.

⁵Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, 7000

East Ave., L-397, Livermore, CA 94551 USA. ⁶RIKEN Omics Science Center, RIKEN

Yokohama Institute 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045,

Japan. ⁷Else Kröner-Fresenius Centre for Nutritional Medicine, Technische Universität

München, D-85350 Weihenstephan, Germany. ⁸Oxford Centre for Diabetes, Endocrinology &

Metabolism, Churchill Hospital, Oxford OX3 7LJ, United Kingdom. ⁹Department of Cell and

Molecular Biology, Karolinska Institute, SE-171 77, Stockholm, Sweden.

*Address correspondence to

Peter Arner, MD, PhD, Professor, Phone +46 8 585 82342, Fax +46 8 58582407, e-mail

peter.arner@ki.se

Kirsty Spalding, PhD, Assistant Professor, Phone +46 (0)70 437 1542, Fax +46 8 324927, e-

mail kirsty.spalding@ki.se

Adipose tissue mass is determined by the storage and removal of triglycerides in adipocytes. Little is known, however, about adipose lipid turnover in humans in health and pathology. To study this *in vivo*, lipid age was determined by measuring nuclear bomb test-derived ^{14}C in adipocyte lipids. We report that during the average ten year life span of human adipocytes, triglycerides are renewed six times. Lipid age is independent of adipocyte size, is very stable across a wide range of adult ages and does not differ between genders. Adipocyte lipid turnover, however, is strongly related to conditions with disturbed lipid metabolism. In obesity, triglyceride removal rate from fat tissue is decreased and the amount of triglycerides stored each year is increased. In contrast, both lipid removal and storage rates are decreased in non-obese patients diagnosed with the most common hereditary form of dyslipidemia, familial combined hyperlipidemia. Lipid removal rate is positively correlated with the capacity of adipocytes to break down triglycerides, as assessed through lipolysis and is inversely related to insulin resistance. Our data support a mechanism in which adipocyte lipid storage and removal play different roles in health and pathology. High storage but low triglyceride removal promotes fat tissue accumulation and obesity. Reduction of both triglyceride storage and removal decreases lipid shunting through adipose tissue and thus promotes dyslipidemia. We identify adipocyte lipid turnover as a novel target for prevention and treatment of metabolic disease.

A major function of adipose tissue is to store and release fatty acids, which are incorporated into adipocyte triglycerides according to whole body energy demands. Body fat mass is determined by the balance between triglyceride storage and removal in adipocytes, by either enzymatic hydrolysis (lipolysis) and subsequent fatty acid oxidation and/or ectopic deposition in non-adipose tissues. Very little is known about the dynamics of these processes in humans. Although isotope tracer methods have been used to estimate lipid turnover in human adipose tissue, these studies have been limited to short-term experimental conditions(1-4). To study long-term adipose tissue lipid turnover *in vivo* and across the adult lifespan, we developed a method to retrospectively determine the age of adipocyte triglycerides in humans. Triglycerides are the major component of the adipocyte lipid droplet. Lipid age was assessed by measuring the ^{14}C content in the lipid compartment of adipocytes from human subcutaneous adipose tissue, the major fat depot in humans. ^{14}C levels in the atmosphere remained remarkably stable until above ground nuclear bomb tests between *ca.* 1955 and 1963 caused a significant increase in ^{14}C relative to stable carbon isotope levels (5) (Fig. 1A). Following the Limited Nuclear Test Ban Treaty signed in 1963, ^{14}C levels in the atmosphere have decreased exponentially. This is not due to radioactive decay ($T_{1/2}$ for ^{14}C is 5,730 years), but to diffusion of ^{14}C out of the atmosphere (6). ^{14}C in the atmosphere oxidises to form CO_2 , which is taken up in the biotope by photosynthesis. Since we eat plants, or animals that live off plants, the ^{14}C content in the atmosphere is directly mirrored in the human body.

Radiocarbon dating has previously been used to study the incorporation of atmospheric ^{14}C into DNA in order to determine the age of different human cell types, including adipocytes (7-11). Here, we compared the incorporation of ^{14}C into adipocyte triglycerides with the dynamic changes in atmospheric ^{14}C described above. Triglyceride age was determined by using a linear lipid replacement model in which the age distribution of lipids within an

individual was exponentially distributed corresponding to a constant turnover rate (per year) (12). The associated mean age, termed lipid age, is the inverse of the turnover rate and reflects the irreversible removal of lipids from adipose stores (Supplement 1).

Earlier studies suggest that triglycerides in adipose tissue form two distinct pools with high or low turnover rates, respectively (13, 14). However, our data, obtained from individuals born before, during and after bomb testing, do not support the hypothesis of dual large lipid pools with different half lives (Fig. 1B). ^{14}C data were modelled according to one or more pools of lipids with different lipid removal rates (details in Supplement 1). The existence of a very small pool of younger lipids cannot be excluded based on data modelling. According to a two-pool model (Supplement 1), the influence on the turnover rate is proportional to the fraction of lipid in the small pool. Triglyceride exchange between adipocytes and other small storage pools can affect turnover estimates. The two-pools model shows, however, that the non-adipose pool can be neglected when it makes up less than 20% of the lipids. Small pools with high turnover are more important for short term (days or weeks) rather than long term (years) triglyceride turnover.

Mean lipid age was 1.6 years (Fig. 2A) which is in the same range as in short term turnover studies (4). The distribution of lipid age was compared with that of adipocyte age reported previously in a comparable cohort (9). The mean age of adipocytes was 9.5 years (Fig. 2B). This implies that triglycerides, on average, are replaced six times during the life span of the adipocyte, enabling a dynamic regulation of lipid storage and mobilization over time.

There is a large variation in adipocyte size within and between individuals (Supplement 2, Table 1; ref 15). However, it is unlikely that the rate of triglyceride removal from adipocytes is important for these variations since lipid age was not related to adipocyte size when set in relation to the body fat mass (Supplementary Fig. 1 A,B), nor was there a difference in lipid age between large and small adipocytes isolated from the same adipose tissue sample

(Supplementary Fig. 1 C,D). These data suggest that there is a continuous exchange of lipids between adipocytes within the adipose tissue which is not dependent on adipocyte size. Fatty acids produced by lipolysis in one adipocyte could, for example, be taken up by adjacent adipocytes and incorporated into their triglycerides.

Lipid age and total fat mass data were used to determine the net triglyceride storage in adipose tissue (kg/year) (see Supplement 1, Box 1). The net amount of lipid stored in adipose tissue each year is the sum of exogenous fat incorporation and endogenous synthesis, minus lipid removal. The removal rate is determined by the hydrolysis of triglycerides (lipolysis) and the irreversible removal of lipids from adipose stores due to fat oxidation. This implies that a high lipid age mirrors low removal rates. No relationship between lipid storage or removal and person age or gender was seen (Supplement 2, Fig. 2 A-D).

Two clinical conditions where altered lipid metabolism is observed were investigated – obesity and familial combined hyperlipidemia (FCHL). Obesity is a world-wide epidemic considered to be a disease burden comparable to smoking. FCHL constitutes the most common hereditary lipid disorder (reviewed in (16)). It has an unknown etiology and is a common hereditary cause of premature coronary heart disease. Adipocyte lipolysis is impaired in both conditions due to decreased cyclic AMP-dependent signaling, the major lipolytic pathway in adipocytes (17-19). In addition, as reviewed (20), both conditions display a similar metabolic phenotype (mixed dyslipidemia, elevated apolipoprotein B and insulin resistance). These clinical characteristics are confirmed in our study cohort (Supplement 2, Table 1). Importantly, FCHL affected individuals may present with a range of body fat levels, however for our analyses only non-obese FCHL patients were selected so as to remove the confound of obesity from the study.

In obese subjects, the rate of triglyceride storage (Fig. 2D) and mean lipid age (Fig. 2C) were markedly increased compared to non-obese individuals. Both lipid age ($r=0.38$,

$p=0.0005$) and triglyceride storage ($r=0.60$, $p<0.0001$) correlated with body mass index when non obese and obese individual were pooled together. Similarly, in non-obese FCHL individuals lipid age was increased to values observed in obesity (Fig. 2C). In contrast to obesity however, the rate of triglyceride storage was markedly decreased compared to non-obese individuals (Fig. 2D). Thus, adipocyte triglyceride turnover is not just a mere reflection of the fat mass. Our data suggests a model where a combination of high storage and low lipid removal rates, as in obesity, facilitates triglyceride accumulation within adipose tissue, thereby promoting the development and/or maintenance of excess body fat mass. Conversely, a low rate of both triglyceride storage and removal, as in FCHL, leads to reduced triglyceride turnover and thereby a decreased ability of adipocytes to store and release fatty acids, despite a normal body fat mass. As discussed in detail elsewhere (21, 22), low lipid turnover in adipose tissue may result in fatty acids being shunted to the liver, which drives the synthesis of apolipoprotein B and increases the circulating levels of triglycerides. Adipocyte triglyceride turnover may also be involved in determining overall insulin effects. Insulin resistance (indirectly measured by the HOMA-IR index, see Supplement 2) and lipid turnover were assessed in 82 individuals. Triglyceride age was strongly related to levels of insulin resistance, though there was no relationship between triglyceride storage and insulin resistance (Fig. 3). There was no significant interaction between groups (lean, obese and non-obese FCHL) as determined by analysis of co-variance, indicating that the rate of triglyceride removal from adipocytes has an impact on whole body insulin sensitivity independent of underlying disorder.

Since lipolysis is a major factor for the removal of lipids from adipose tissue we investigated the ability of the cyclic AMP system to activate lipolysis *in vitro* in adipocytes isolated from lean and obese individuals and compared this with *in vivo* measurements of lipid storage and removal (Fig. 4). Lipolysis activation was negatively correlated with

triglyceride removal (lipid age) but was not related to the rate of triglyceride uptake (lipid storage). This was irrespective of whether lipolysis was induced using a cyclic AMP analogue (Fig 4 A,B), by activating endogenous adenylate cyclase (using forskolin; Fig. 4 C,D) or by administration of a synthetic beta adrenoceptor-selective catecholamine (isoprenaline; Fig 4. E,F). These data suggest that lipolysis determines lipid turnover in adipocytes by regulating the rate of triglyceride removal. The impact of subsequent fatty acid oxidation could not be examined in this study, however decreased lipid oxidations is frequently observed in obesity (23, 24).

We are in the midst of a global epidemic of obesity with negative health and socio-economic consequences. We propose adipose triglyceride turnover as a novel target for the prevention and treatment of excess body fat and possibly its consequences for insulin resistance. The novel insights into abnormal triglyceride turnover in FCHL patients may also suggest novel treatment strategies for this complex disease targeting adipocytes.

METHODS SUMMARY

Subjects: Subcutaneous adipose tissue was obtained from two patient cohorts. Patient selection and collection of clinical data are described in Supplement 2.

Preparation of lipids: Triglycerides were extracted from pieces of adipose tissue or isolated adipocytes. Details of lipid extraction and adipocyte isolation are given in Supplement 2. Extracted lipids were subjected to accelerator mass spectrometry analysis, as described in Supplement 2.

Data analysis: Calculations between lipid turnover and clinical or adipocyte phenotypes are described in Supplement 2. Calculations of lipid age and net lipid uptake by adipose tissue

are described in detail in Supplement 1. Conventional statistical methods were used to summarise and compare data.

(1535 words)

REFERENCES

1. **Klein RA, Halliday D, Pittet PG** 1980 The use of 13-methyltetradecanoic acid as an indicator of adipose tissue turnover. *Lipids* 15:572-579
2. **Marin P, Oden B, Bjorntorp P** 1995 Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. *The Journal of clinical endocrinology and metabolism* 80:239-243
3. **Marin P, Rebuffe-Scrive M, Bjorntorp P** 1990 Uptake of triglyceride fatty acids in adipose tissue in vivo in man. *European journal of clinical investigation* 20:158-165
4. **Strawford A, Antelo F, Christiansen M, Hellerstein MK** 2004 Adipose tissue triglyceride turnover, de novo lipogenesis, and cell proliferation in humans measured with 2H₂O. *American journal of physiology* 286:E577-588
5. **Nydal R, Lovseth K** 1965 Distribution of radiocarbon from nuclear tests. *Nature* 206:1029-1031
6. **Levin I, Kromer B** 2004 The tropospheric 14CCO₂ level in mid latitudes of the northern hemisphere (1959-2003). *Radiocarbon* 46:1261-1272
7. **Spalding KL, Bhardwaj RD, Buchholz BA, Druid H, Frisen J** 2005 Retrospective birth dating of cells in humans. *Cell* 122:133-143
8. **Perl S, Kushner JA, Buchholz BA, Meeker AK, Stein GM, Hsieh M, Kirby M, Pechhold S, Liu EH, Harlan DM, Tisdale JF** 2010 Significant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating. *The Journal of clinical endocrinology and metabolism* 95:E234-239
9. **Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, Blomqvist L, Hoffstedt J, Naslund E, Britton T, Concha H, Hassan M, Ryden M, Frisen J, Arner P** 2008 Dynamics of fat cell turnover in humans. *Nature* 453:783-787
10. **Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S, Zupicich J, Alkass K, Buchholz BA, Druid H, Jovinge S, Frisen J** 2009 Evidence for cardiomyocyte renewal in humans. *Science (New York, NY)* 324:98-102
11. **Bhardwaj RD, Curtis MA, Spalding KL, Buchholz BA, Fink D, Bjork-Eriksson T, Nordborg C, Gage FH, Druid H, Eriksson PS, Frisen J** 2006 Neocortical neurogenesis in humans is restricted to development. *Proceedings of the National Academy of Sciences of the United States of America* 103:12564-12568
12. **Bernard S, Frisen J, Spalding KL** 2009 A mathematical model for the interpretation of nuclear bomb test derived 14C incorporation in biological systems. *Nuclear Instruments and Methods in Physics Res B*
13. **Ekstedt B, Olivecrona T** 1970 Uptake and release of fatty acids by rat adipose tissue: last in to first out? *Lipids* 5:858-860
14. **Kerpel S, Shafrir E, Shapiro B** 1961 Mechanism of fatty acid assimilation in adipose tissue. *Biochimica et biophysica acta* 46:495-504
15. **Bjorntorp P** 1974 Effects of age, sex, and clinical conditions on adipose tissue cellularity in man. *Metabolism: clinical and experimental* 23:1091-1102
16. **SM G, Chait A, Brunzell JD** 1987 Familial combined hyperlipidemia workshop. *Arteriosclerosis* 7:203-207
17. **Langin D, Dicker A, Tavernier G, Hoffstedt J, Mairal A, Ryden M, Arner E, Sicard A, Jenkins CM, Viguerie N, van Harmelen V, Gross RW, Holm C, Arner P** 2005 Adipocyte lipases and defect of lipolysis in human obesity. *Diabetes* 54:3190-3197

18. **Reynisdottir S, Eriksson M, Angelin B, Arner P** 1995 Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia. *The Journal of clinical investigation* 95:2161-2169
19. **van der Kallen CJ, Voors-Pette C, Bouwman FG, Keizer HA, Lu JY, van de Hulst RR, Bianchi R, Janssen MJ, Keulen ET, Boeckx WD, Rotter JI, de Bruin TW** 2002 Evidence of insulin resistant lipid metabolism in adipose tissue in familial combined hyperlipidemia, but not type 2 diabetes mellitus. *Atherosclerosis* 164:337-346
20. **Ayyobi AF, Brunzell JD** 2003 Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. *The American journal of cardiology* 92:27J-33J
21. **Arner P** 1997 Is familial combined hyperlipidaemia a genetic disorder of adipose tissue? *Current opinion in lipidology* 8:89-94
22. **de Graaf J, Veerkamp MJ, Stalenhoef AF** 2002 Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids. *Journal of the Royal Society of Medicine* 95 Suppl 42:46-53
23. **Blaak EE, Hul G, Verdich C, Stich V, Martinez A, Petersen M, Feskens EF, Patel K, Oppert JM, Barbe P, Toubro S, Anderson I, Polak J, Astrup A, Macdonald IA, Langin D, Holst C, Sorensen TI, Saris WH** 2006 Fat oxidation before and after a high fat load in the obese insulin-resistant state. *The Journal of clinical endocrinology and metabolism* 91:1462-1469
24. **Houmard JA** 2008 Intramuscular lipid oxidation and obesity. *Am J Physiol Regul Integr Comp Physiol* 294:R1111-1116

Supplementary Information

Supplement 1: Modelling lipid turnover

Supplement 2: Patient information and tissue processing

Acknowledgements

This study was supported by the Swedish Research Council, Swedish Foundation for Strategic Research, Swedish Heart and Lung foundation, Novo Nordic Foundation, Swedish Diabetes Foundation, Diabetes Research Program at the Karolinska Institutet, Swedish Cancer Society, Uppsala BIO, Sweden, NIH/NCCR Grant RR13461 and by the projects ‘Hepatic and adipose tissue and functions in the metabolic syndrome’ (HEPADIP, <http://www.hepadip.org/>) and ADAPT “Adipokines as drug targets to combat adverse effects

of excess adipose tissue” (<http://www.adapt-eu-net>), which were supported by the European Commission as an Integrated Project under the 6th and the 7th Framework Programmes (contract LSHM-CT-2005-018734 and contract HEALTH-F2-2008-201100,). This work was performed in part under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under contract DE-AC52-07NA27344. The authors would like to acknowledge Eva Sjölin, Kerstin Wåhlén, Britt-Marie Leijonhufvud, Katarina Hertel and Yvonne Widlund for excellent technical assistance. A special thanks to Dr. Fanie Barnabé-Heider and Professor Jonas Frisé for useful comments on the manuscript.

Author Contributions

K.L.S. and P.A. designed the study and wrote together with K.F and S.B. the manuscript. M.R. co-ordinated writing and data assembly. S.B. and E.A. were responsible for the modelling. K.L.S. performed sample preparation. M.S., B.B., P.S. and J.L. performed ¹⁴C accelerator mass spectrometry measurements. P.A., M.E., T.S. and H.H. collected clinical material.

Author Information

Correspondence and requests for materials should be addressed to P.A. (peter.arner@ki.se) or K.L.S. (kirsty.spalding@ki.se).

The authors declare no competing interests.

LEGEND TO FIGURES

Fig. 1. *Atmospheric ^{14}C over time.* A: Above ground nuclear bomb testing during the period of the cold war caused an increase in atmospheric levels of ^{14}C . These values decreased exponentially following implementation of a limited world-wide test ban treaty in 1963 (blue curve). Lipid age is determined by measuring ^{14}C levels in lipids (1) and plotting this value against the bomb-curve (2) to determine **the difference between** the year corresponding to the atmospheric ^{14}C concentration (3) **and the biopsy collection date (dashed line)**. Atmospheric ^{14}C levels are presented as $^{14}\text{C}/^{12}\text{C}$ ratios in units of Fraction Modern (for a definition of ‘Modern’ see Supplement 2). B: Lipid **age and** turnover do not change as a function of person age. Lipid age is shown for three individuals born in 1940.2, 1959.9 and 1967.9. Lipid age was shown to be the same for all individuals, despite markedly different subject ages. Fat biopsies **were** collected from all individuals on the same date (dashed vertical line). The solid vertical line indicates the date of birth (DOB). The small dashed lines show the ^{14}C lipid value for each individual (only two ^{14}C lipid values are shown, since two of them **were equal**).

Fig.2 *Adipocyte age and lipid turnover in subcutaneous fat.* A: Distribution of values for lipid age in healthy non-obese or obese individuals. B: The distribution of values for human adipocyte age. Data are obtained from a previous publication (see main text). C: Lipid age in 48 non-obese, 30 obese and 13 non-obese FCHL subjects. D: Lipid storage in the same cohort as in C. T-bars indicate

standard error. Overall effect is $p < 0.0001$ by ANOVA in C and D. Results in graphs are from post-hoc test. Data are from Cohort 1 (See Suppl. 2).

Fig. 3 *Correlation between adipocyte triglyceride turnover and insulin resistance (HOMA-IR index).* A linear regression analysis was performed on all individuals from cohort 1 having insulin resistance measures ($n=82$). HOMA-IR was correlated with lipid storage (A) and lipid age (B). The relationship between lipid age and HOMA-IR remained significant when body mass index (BMI), gender or group (non-obese, obese, FCHL) were included in the analysis (partial $r=0.41$, $p=0.006$ with BMI using multiple regression analysis and $F=16.6$, $p=0.0001$ $F=4.8$, $p=0.03$ for gender or group, respectively, using ANCOVA).

Fig. 4 *Correlation between lipid turnover and adipocyte lipolysis.* A and B: Lipid age and lipid removal rates with dibutyryl cyclic AMP (A,B), which is a phosphodiesterase resistant and stable cyclic AMP analogue stimulating the protein kinase A complex; forskolin (C,D), a stimulator of adenylate cyclase which stimulates cyclic AMP production and isoprenaline (E,F), a synthetic beta adrenergic receptor-selective catecholamine acting as a lipolytic agents. Linear regression analysis was used. Data are from non-obese and obese individuals from cohort 1. Data with lipolytic agents versus lipid age were significant when analysed using body mass index as covariate in multiple regression analysis (partial $r=-0.35$; $p \leq 0.004$).

Suppl 1 Fig. 1 "Last In, First Out" scenario. (*Left*) Lipid age distribution (log-scale) for uniform lipid turnover (solid) and LIFO lipid turnover (dashed) with $t = 40$

years. (*Right*) Relation between subject age and the average lipid age. $K_{out} = 0.59/\text{year}$, $k_1 = 112/\text{year}$, and $k_0 = 18$ years in both panels.

Suppl 2 Fig.1 *Relationship between adipocyte size and lipid age.* A and B: Influence of adipocyte cellularity on lipid age. Individuals were assigned a morphometric value, which is the difference between the measured adipocyte volume for the individual minus the average adipocyte volume for all subjects (see Supplemental 2). This analysis was carried out across the full range of body masses. Positive values indicate larger adipocytes than expected (fewer but larger adipocyte = hypertrophy). Negative values indicate smaller adipocytes than expected (many but smaller adipocytes =hyperplasia). A shows individual values compared by linear regression analysis. B shows data (mean \pm standard error) with morphology as a dichotomous variable. An unpaired t-test was used. C and D: Isolated subcutaneous adipocytes were fractioned into small (fraction 1) or very large (fraction 4) samples. Adipocyte volume (C) and adipose lipid age (D) were compared. Values are mean \pm standard error. A paired t-test was used. Data in A and B are from Cohort 1 and C and D are from Cohort 2.

Suppl 2 Fig. 2 *Influence of person age and gender on subcutaneous adipose lipid turnover.*

No relationship between person age and lipid age (A) or lipid storage (B) was seen (linear regression analysis). Gender had no influence lipid age (C) or lipid storage (D) (unpaired t-test). Values are mean \pm standard error. Data are from Cohort

Figure 1





Figure 2




Figure 3














Figure 4



Supplementary Figure 1



Supplementary Figure 2



Supplement. 2. Table 1. Clinical data of individuals subdivided according to their diagnosis (Cohort 1). BMI cut-off point for obesity is >30 kg/m². Values are mean + SE.

Group	Males/ females	Age, years	BMI, kg/m ²	Body fat, %	HOMA index*	Total plasma cholesterol, mmol/l	Plasma HDL cholesterol, mmol/l	Plasma triglyceride, mmol/l*	ApoB, g/l	Fat cell volume ,pico-litres	Fat cell mor- phology values, picolitres
Non- obese n=48	12/36	35 ± 9	23.6 ± 2.1	28 ± 7	1.5 ± 0.8	5.0 ± 1.0	1.5 ± 0.4	1.0 ± 0.4	0.9 ± 0.2	495 ± 150	-2 ± 152
Obese N=30	7/23	37 ± 10	40.2 ± 6.7	53 ± 15	6.3 ± 5.5	5.5 ± 1.1	1.1 ± 0.3	2.5 ± 1.8	1.2 ± 0.2	865 ± 165	49 ± 197
FCHL n=13	10/3	44 ± 10	25.5 ± 2.3	28 ± 9	2.4 ± 1.5	7.2 ± 1.2	1.1 ± 0.3	4.6 ± 4.9	1.5 ± 0.4	495 ± 140	-25 ± 132
p-value ANOVA		0.009	<0.0001	<0.001	<0.001	<0.0001	0.0004	<0.0001	<0.0001	<0.0001	0.31
Post-hoc p-value											
Non- obese obese		0.36	<0.0001	<0.0001	<0.0001	0.07	0.0005	0.009	<0.0001	<0.0001	-
Non- obese FCHL		0.002	0.13	0.67	0.02	<0.0001	0.002	<0.0001	<0.0001	0.99	-
Obese- FCHL		0.02	<0.0001	<0.0001	<0.0001	<0.0001	0.93	0.01	0.001	<0.0001	-

*10 log transformed values were used in the statistical tests. Results were compared by ANOVA and Fisher's PLSD post-hoc test. **similar results were obtained with non parametric test.

2011-06-16 #1

Supplement 2. Table 2. Clinical data of subjects undergoing investigations of their subcutaneous adipocytes when fractionated according to fat cell size (Cohort 2).

Gender (F/M)	5/2
BMI (kg/m ²) (median and range)	30 (25-36)*
Age (years) mean \pm standard error	34 \pm 3

*3 obese and 4 non-obese were investigated.

Supplement 1: Modelling Lipid Turnover

Summary of the model for lipid turnover

Fat is mainly stored as lipids in adipocytes (fat cells). Change in the size of the fat mass over time is determined by the balance between the amount of lipid storage by adipocytes and the rate of lipid removal from the body. This is expressed by the differential equation


$$\frac{dF(t)}{dt} = K_{in}(t) - R(t, F(t)), \quad (1)$$

where $F(t)$ is the total fat mass (kg), $K_{in}(t)$ is the amount of lipid uptake by the adipose tissue every year (kg/year) and $R(t, F(t))$ is the amount of lipids removed every year (kg/year). The time t is the age of the subject in years. The amount of lipids removed each year clearly depends on the total fat mass, so it is useful to measure the relative removal rate per unit fat mass by dividing R with the total fat mass. The resulting value, $K_{out}(t) = R(t, F(t))/F(t)$, defines the instantaneous turnover rate (per year). $K_{out}(t)$ might change over time, but for $K_{in}(t) = K_{in}$ and $K_{out}(t) = K_{out}$ fixed, the total fat mass always reaches a constant steady state F . This happens when $K_{in} = K_{out}F$. Thus, a larger value of K_{in} sets the mass at a larger value (Supp. 1, Fig. 1A) and a larger value of K_{out} sets the mass at a smaller value (Supp. 1, Fig. 1B). Once the total fat mass is at steady state, the turnover rate K_{out} defines how quickly lipids are replaced in adipocytes. The lipid age (the average time lipids have spent in adipocytes) is the inverse of the turnover rate: $a = 1/K_{out}$ (in years, Supp. 1, Fig. 1C).

This interpretation of the turnover has a meaning only at steady state, and a change in fat mass can affect lipid age. A sudden increase in lipid storage will reduce the average age while the total fat mass is increasing, but only transiently (Supp. 1, Fig. 1D). Once the fat mass has reached a new steady state, the age goes back to its original value, as it does not depend on lipid storage. Similarly, a sudden decrease in lipid storage will increase transiently the average age (Supp. 1, Fig. 1E). Any permanent change in lipid removal rate, however, would affect the average age and its steady state value (Supp. 1, Fig. 1C). Below, we describe in details the mathematical model used for estimating lipid turnover from ^{14}C data.

Mathematical model of lipid turnover

Lipid age was estimated in two different ways. First, the ^{14}C level of each sample was reported on the atmospheric ^{14}C level curve (bomb curve) and the difference between the collection date and the corresponding date was taken. This was called bomb curve age a_{BC} ¹. For the second method, a linear lipid replacement model was used, in which the age distribution of lipid within one subject is exponentially distributed. This corresponds to a constant turnover rate, denoted K_{out} . The associated mean age is $a_{to} = 1/K_{out}$. This age



Supp. 1, Fig. 1. Lipid turnover in adipocytes.

corresponds to the average age of lipids in one individual. An alternative model, where lipids follow a Last In, First Out scheme, has been tested but does not appear essential to describe the data. A very strong similarity was found between a_{bc} and a_{to} , suggesting that the modelling captures the essential of the lipid dynamics in the adipose tissue.

We assumed that the total body fat mass F evolves according to a balance equation,

$$\frac{dF}{dt} = K_{in} - R, \quad (2)$$

where K_{in} is the net lipid uptake by the adipose tissue (units: kg/year), and R is the net lipid removal rate (units: kg/year). The relative removal rate normalized by the total fat mass is $K_{out} = R/F$. The parameter K_{out} controls the rate at which lipids are replaced, and is termed turnover rate. If the total fat mass does not change too fast, the fat mass is said to be at steady state. The steady state assumption means that the left-hand side of equation (2) is zero. This implies that the body fat mass is determined by the balance between lipid storage and lipid turnover:

$$F = \frac{K_{in}}{K_{out}} \quad (3)$$

Under the steady-state assumption, the average age of lipids is $a_{to} = 1/K_{out}$ (see “Section Estimating the Turnover from ^{14}C Data” below for details). Then, we have that the total fat mass satisfies

$$F = K_{in} a_{to}. \quad (4)$$

This relation defines the relation between the average age of lipids, the total fat mass and the net amount of lipid uptake.

Estimating the Turnover from ^{14}C Data

The method used here has been adapted from a general model for estimating turnover rates in biological samples^{2,3}. ^{14}C is continuously integrated into lipids that enter adipocytes. In order to track the change in ^{14}C content over time, it is helpful to recast equation (2) into a linear structured differential equation

$$\frac{\partial f(t, a)}{\partial t} + \frac{\partial f(t, a)}{\partial a} = -K_{out}f(t, a). \quad (5)$$

$$f(t, 0) = K_{in}. \quad (6)$$

The function $f(t, a)$ is the density of lipids with age a at time t and is related to the fat mass in the following way:

$$F(t) = \int f(t, a)da. \quad (7)$$

This is a one-compartment model in which lipids enter adipose tissue at age 0 and enter only once; lipids are not recycled.

The left-hand-side terms are conservation terms saying that lipids advance in age at the same rate as time. The right-hand-side term accounts for the removal of lipids. A boundary condition describes the constant uptake of new lipids ($f(t, 0) = K_{in}$). This model has two parameters, K_{in} and K_{out} , which are possibly nonlinear. To specify the system completely, we need initial data, i.e. the age distribution of lipids at subject age $t = 0$. We assume that the total fat mass at birth is negligible $f(0, a) = 0$.

For each subject, two independent measurements are available: the total fat mass (F) and the ^{14}C abundance in lipids. The ^{14}C abundance allows one to calculate the parameter K_{out} . The associated ^{14}C abundance associated to a lipid sample collected at time t_d is

$$C = \frac{\int_0^{t_d-t_b} K(t_d - a)f(t, a)da}{F(t)} \quad (8)$$

The value t_b is the time of birth of the subject. For lipid turnover, it is assumed no lipid is left from birth, due to the relatively rapid turnover. The parameter K_{in} cancels out so the only parameter left is K_{out} . This simple model thus allows individual estimates of K_{out} , the turnover rate. The function K is the atmospheric ^{14}C abundance curve, or the ‘‘bomb curve’’.

Based on that system, the average age of lipids with turnover rate K_{out} in a subject of age t is

$$\langle a \rangle_t = \frac{-t \exp(-K_{out}t) + (1 - \exp(-K_{out}t))/K_{out}}{1 - \exp(-K_{out}t)} \quad (9)$$

The average lipid age depends strongly on t in young subjects, but as t gets larger, $\exp(-K_{out}t)$ gets very small and the average lipid age approaches $a_{to} = 1/K_{out}$. For the turnover values measured here, this approximation is valid for ages $t > 10$ years (see right panel of Supp. 1, Figure 2). All subjects were adults, so we used this approximation to define the average lipid age.

We compared the lipid age obtained with this turnover method with the lipid age obtained by reading off the bomb curve. The two methods yielded very similar estimates (correlation $\rho = 0.99$), but the bomb curve age gave slightly larger estimates (difference 0.08 years, p-value < 0.001). Although the estimates were slightly different, these results show that the turnover method did not introduce unwanted artifacts.

Last In, First Out Scenario


In the previous section, we assumed that the turnover rate K_{out} was constant. However, it has been proposed that lipids are not distributed uniformly in the adipocytes, but that last entered lipids are more likely to be removed from the cell than older lipids. This scenario is called ‘‘Last In, First Out’’, or LIFO^{4,5}. In terms of the model here, this is expressed as an age-dependent K_{out} . Last entered (young) lipids have a higher turnover than old lipids, thus the turnover must be a decreasing function of lipid age. One possible such function is the following,

$$k_{out}(a) = \frac{k_0 k_1}{k_1 + a}. \quad (10)$$

(Small letters are used to distinguish from the default one-compartment model.) When the turnover is uniform with age a , the average lipid age is directly related to the turnover $a_{to} = 1/K_{out}$, as above. In the ‘‘Last In, First Out’’, or LIFO scenario, the average lipid age in a subject aged t years is

$$a_{LIFO} = \frac{[-k_0 k_1 + 1] [(k_1 + t)^{-k_0 k_1 + 2} - k_1^{-k_0 k_1 + 2}]}{[-k_0 k_1 + 2] [(k_1 + t)^{-k_0 k_1 + 1} - k_1^{-k_0 k_1 + 1}]} - k_1. \quad (11)$$

The parameter k_1 control at which age the turnover is half what it was at age 0 (k_0). From equation (11), the larger the value of k_1 , the weaker the LIFO effect. It is therefore interesting to see what happens when k_1 become close to the critical value $k_1 = 2/k_0$. For example, we have chosen $k_1 = 1/12$ year, and $k_0 = 18$ per year and $t = 40$ years. For these values, the average age of lipid is 1.74 years, close to the average value calculated for all samples, but the distribution of ages is much wider (Supp. 1, Figure 2, left panel). With these values, there is a strong subject age-depedence due to the slow aging of old lipids that never get replaced (Supp. 1, Figure 2, right panel). Therefore, if the LIFO effect was important, there should be a slow lipid aging amongst older subjects. The absence of such a correlation speaks against the importance of LIFO in determining lipid



Supp. 1, Fig. 2. “Last In, First Out” scenario. (*Left*) Lipid age distribution (in normalized log-scale amount per year), for the uniform turnover (solid) and LIFO (dashed) with $t = 40$ years. Each line represents the relative amount of lipid at a given age. (*Right*) Evolution with subject age of the average lipid age. $K_{out} = 0.59/\text{year}$, $k_1 = 1/12$ year, and $k_0 = 18$ years in both panels.

age. With a uniform turnover rate, the lipid age quickly reaches a steady state in adults, in agreement with the measured lipid ages.

We have fitted the LIFO scenario to the ^{14}C samples. The best fit for the whole population (in the least-square sense, the error is denoted SSE) yielded $k_0 = 0.63$ per year and $k_1 = 36$ years (SSE = 0.014). This large value for k_1 means that the turnover rate is almost uniform. It is still possible that the rapid compartment is fast but small with respect to the whole tissue. To see if this could be compatible with our data, we constrained parameter k_1 to be short ($k_1 = 1$ year), and fitted the parameter . The result, $k_0 = 2.9$ per year (SSE = 0.022) was not as good as the optimal fit, but is still acceptable. Lipid age would be of average 1.05 years, somewhat younger than in a homogeneous pool. Therefore, although the best model seems to be a homogeneous pool of lipid, the data are compatible with the existence of a compartment with a rapid turnover. Assuming the existence of such a compartment does not change the results and conclusion obtained with the constant turnover scenario, but would have a important effect on measurements obtained by short-term labelling studies.

In summary, there is no indication that the LIFO is better than the uniform turnover. However, we cannot rule out that a small proportion of the lipids is turning over rapidly.

Two-compartment models

The model used to estimate turnover rate is a one-compartment model. We look here at the effect of having two different pools of lipids, with different turnover rates and possibly exchanges between to two pools. At steady states, the ages distributions for the two pools are given by two coupled linear differential equations

$$\begin{aligned}\frac{\partial p_1(t, a)}{\partial a} &= - (k_o^1 + k_{12})p_1(t, a) + k_{12}p_2(t, a), \\ \frac{\partial p_2(t, a)}{\partial a} &= - (k_o^2 + k_{21})p_2(t, a) + k_{21}p_1(t, a), \\ p_1(t, 0) &= k_{in}^1, \\ p_2(t, 0) &= k_{in}^2.\end{aligned}$$

The solution to this system is

$$p_1(t, a) = q_1 e^{-\lambda_1 a} + q_2 e^{-\lambda_2 a},$$

where

$$\begin{aligned}q_1 &= -\frac{1}{\sqrt{d}} \left[\frac{k_{in}^1}{2} \left(k_o^2 + k_{21} - k_o^1 - k_{12} - \sqrt{d} \right) + k_{in}^2 k_{21} \right], \\ q_2 &= \frac{1}{\sqrt{d}} \left[\frac{k_{in}^1}{2} \left(k_o^2 + k_{21} - k_o^1 - k_{12} + \sqrt{d} \right) + k_{in}^2 k_{21} \right], \\ \lambda_1 &= \frac{1}{2} \left(k_o^2 + k_{21} + k_o^1 + k_{12} + \sqrt{d} \right), \\ \lambda_2 &= \frac{1}{2} \left(k_o^2 + k_{21} + k_o^1 + k_{12} - \sqrt{d} \right), \\ d &= (k_o^2 + k_{21} - k_o^1 - k_{12})^2 + 4k_{12}k_{21}.\end{aligned}$$

Therefore, adipocyte lipids are removed at two different rates, λ_1 and λ_2 , and the relative importance (weight) of each removal rates are given by the coefficients of each of the exponentials in the equation for p_1 above. The average age in pool 1 is therefore

$$\begin{aligned}\langle a \rangle_1 &= \frac{\int_0^\infty a p_1(t, a) da}{\int_0^\infty p_1(t, a) da}, \\ &= \frac{q_1/\lambda_1^2 + q_2/\lambda_2^2}{q_1/\lambda_1 + q_2/\lambda_2}.\end{aligned}$$

A similar relation exists for pool 2, with indices 1 and 2 inverted.

Effect of a small pool of high turnover lipids

In the LIFO model, there was a continuum of decreasing turnover rates with lipid ages. To quantify the effect of a small pool of higher turnover lipids, we looked at the linear two-compartment model, in which young lipids (pool 2) are either rapidly removed or enter the low turnover pool (pool 1). According to these assumptions, no old lipid reenter the young lipid pool ($k_{12} = 0$) and all old lipids have first been in the young pool ($k_{in}^1 = 0$). Moreover, we assumed that the ^{14}C measured gives us an estimate of the mean age of the total lipid content, in pools 1 and 2. From the equation above and the assumptions on parameters, the average age of lipids in pool 1 is

$$\langle a \rangle_1 = \frac{(k_o^2 + k_{21} + k_o^1)}{(k_o^1)(k_o^2 + k_{21})}.$$

Similarly, the average age in pool 2 is

$$\langle a \rangle_2 = \frac{1}{k_o^2 + k_{21}}.$$

The fractions of lipids in pool 1 and 2 are respectively

$$s_1 = \frac{k_{21}}{k_{21} + k_o^1},$$

$$s_2 = \frac{k_o^1}{k_{21} + k_o^1}.$$

The average lipid age in the two pools is

$$\begin{aligned} \langle a \rangle_{two} &= s_1 \langle a \rangle_1 + s_2 \langle a \rangle_2 \\ &= \frac{k_{21}}{k_{21} + k_o^1} \frac{(k_o^2 + k_{21} + k_o^1)}{(k_o^1)(k_o^2 + k_{21})} + \frac{k_o^1}{k_{21} + k_o^1} \frac{1}{k_o^2 + k_{21}} \end{aligned}$$

We are interested in comparing the turnover rate obtained in the one-compartment model K_{out} and the slow turnover obtained with the two-compartment model k_o^1 , for a given value of the total average lipid age. Therefore we equate the two average values: $1/K_{out} = \langle a \rangle_{two}$, and look at the ratio between k_o^1 and K_{out} . To do that, we rewrite the high turnover parameter as $k_o^2 = zk_o^1$ and the transfer rate as $k_{21} = (1 - s_2)k_o^1/s_2$. Then we obtain,

$$\begin{aligned} \frac{k_o^1}{K_{out}} &= (1 - s_2) \frac{z + 1/s_2}{z + (1 - s_2)/s_2} + \frac{s_2}{z + (1 - s_2)/s_2} \\ &= \frac{(1 - s_2)z + 1/s_2 - 1 + s_2}{z + (1 - s_2)/s_2}. \end{aligned}$$

From the assumptions, we know that s_2 is small (small high turnover pool) and $r \gg 1$ (high turnover). For large values of z , the ratio $k_o^1/K_{out} \approx 1 - s_2$, and for $z = 1$, the ratio $k_o^1/K_{out} = 1$. This means that for small values of z , the ratio between the turnover rates is close to one (s_2 being very small) and for large values of z , the error on turnover rates is of the order of s_2 . In fact, the the removal rate k_o^1 underestimates the true turnover rate K_{out} because the lipids enter the slow turnover pool with a positive age.

We conclude that the error made by using the one-compartment model if there is a small lipid pool with a high turnover rate is at worst of the same order as the size of the high turnover lipid pool.

Non-adipocyte compartment for lipids

A small quantity of lipids is stored in non-adipocyte compartments. If there is exchange between the two physiological compartment, that can affect the measured turnover rate. Only the adipocyte lipids (pool 1) is measured so we are interested in the average age of compartment 1 only. The average lipid age in pool 1 is

$$\langle a \rangle_1 = \frac{[k_o^2 + k_o^1 + k_{12} + k_{21}]k_{21}k_{in}^2 + [2k_o^2k_{21} + k_{12}k_{21} + (k_o^2)^2 + (k_{21})^2]k_{in}^1}{[k_o^2k_{12} + k_o^2k_o^1 + k_{21}k_o^1]k_{21}k_{in}^2 + [k_o^2k_{12}k_{21} + 2k_{21}k_o^2k_o^1 + (k_o^2)^2(k_{12} + k_o^1) + (k_{21})^2k_o^1]k_{in}^1}. \quad (12)$$

The expression above cannot be related easily to the lipid age $1/K_{out}$. Because lipids can cycle between the two pools, the lipid removal rate from one pool is not well always defined. Using the production rate ratio $w = k_{in}^2/k_{in}^1$, the expression (12) can be reexpressed with one parameter less. The ratio between pool 2 and pool 1 is

$$r_2 = \frac{k_o^1w + k_{12}w + k_{12}}{k_{21}w + k_o^2 + k_{21}}.$$

It is biologically relevant to look at the behavior of $\langle a \rangle_1$ when r_2 is small (Supp. 1, Figure 3, left panel). For small values of r_2 (when $r_2 \rightarrow 0$), the average age simplifies to

$$\langle a \rangle_1 \approx \frac{k_o^2 + k_{21}}{k_o^2k_{12} + k_o^1k_o^2 + k_o^1k_{21}}. \quad (13)$$

This last expression is much more tractable, and does not depend on the production rates anymore. However, one must make sure that the production rate ratio is positive, so this expression is valid for r_2 between the two values

$$r_2(w = 0) = \frac{k_{12}}{k_o^2 + k_{21}}, \quad (14)$$

and

$$r_2(w = \infty) = \frac{k_o^1 + k_{12}}{k_{21}}. \quad (15)$$

It is still difficult to relate $\langle a \rangle_1$ with the parameters but we can distinguish three limiting cases. These cases are only valid for small values of r_2 (in practice, we have found that $r_2 < 0.20$ is small enough).

1) $k_{12} \rightarrow 0$ or $k_o^2 \rightarrow 0$ or $k_{21} \rightarrow \infty$. Then $\langle a \rangle_1 = 1/k_o^1$. All lipids go quickly to the adipocyte pool and the lipid age is only controlled by the removal rate in the adipocyte pool. Therefore the two-compartment model reduces to the one-compartment model by setting $K_{out} = k_o^1$.

2) $k_{21} \rightarrow 0$ or $k_o^2 \rightarrow \infty$. Then $\langle a \rangle_1 = 1/(k_o^1 + k_{12})$. In this case, the non-adipocyte pool quickly removes all lipids, which are not recycled, so the turnover in the adipocyte pool is the removal rate k_o^1 + the exchange rate k_{12} . Therefore the two-compartment model reduces to the one-compartment model by setting $K_{out} = k_o^1 + k_{12}$.

3) Other cases. Then

$$\frac{1}{k_o^1 + k_{12}} \leq \langle a \rangle_1 \leq \frac{1}{k_o^1}. \quad (16)$$

This interval gets large when k_{12} is much larger than k_o^1 , i.e. adipocyte lipids are quickly transferred to the non-adipocyte pool. Then the average age is best expressed by equation (13).

As noted in the main text, the estimate of lipid age using the bomb curve profile (a_{BC}) and the one-compartment model (a_{to}) are similar, meaning that the estimated lipid age probably reflect well the real lipid age. The discussion above therefore only has an impact on the estimated turnover rate. From the ^{14}C data, one cannot know if lipids going out of the adipocyte pool are stored in a second pool before being removed from the body, so the estimate for K_{out} can only be interpreted as a general removal rate, which corresponds either to k_o^1 or to $k_o^1 + k_{12}$. In practice, it does not matter where lipids go, as long as they are not recycled to the adipose tissue. A case where lipid recycling is important is when k_{21} , k_o^2 and k_{12} are large. Then the ^{14}C -measured turnover rate K_{out} will be in the interval $(k_o^1, k_o^1 + k_{12})$. However, in that case, the turnover rate of pool 1 is not well defined. One may tentatively define the turnover rate as the inverse of the average lipid age, as in the one-compartment model,

$$K_{out} \equiv \frac{k_o^2 k_{12} + k_o^1 k_o^2 + k_o^1 k_{21}}{k_o^2 + k_{21}}.$$

Unfortunately, because of lipid exchange, the turnover cannot be expressed in term of pool 1 parameters only. Nevertheless, for small values of r_2 , numerical simulation show that the this approximation of the turnover rate is very close to the turnover rate computed

from the two-compartment model. We ran the two-compartment model with 125 different parameter sets over 4 orders of magnitude and found that for $r_2 < 0.20$ the turnover rates were well approximated (Supp. 1, Figure 3, right panel).


Data Analysis

Equation (4) establishes the relation between fat mass, lipid uptake and lipid age. Fat mass and lipid age have been estimated independently, so the annual uptake rate can be estimated as well. The turnover K_{out} was calculated using a direct search method for each ^{14}C sample with Matlab (Naticks, MA).

Analysis was based on 157 samples, of which clinical data was available for 92 individuals. One sample per subject was used for lipid turnover analysis. Total lipid storage K_{in} was calculated as $K_{in} = K_{out}F$, where the total fat mass F was obtained independently from K_{out} . One of the samples had a calculated age of 8.5 ± 0.6 years. This sample was an extreme outlier and was not included in the statistical analysis presented in the main text.

References

1. Spalding, K., Bhardwaj, R., Buchholz, B., Druid, H. & Frisén, J. Retrospective birth dating of cells in humans. *Cell* **122**, 133–143 (2005).
2. Spalding, K. *et al.* Dynamics of fat cell turnover in humans. *Nature* **453**, 783–787 (2008).
3. Bernard, S., Frisén, J. & Spalding, K. A mathematical model for the interpretation of nuclear bomb test derived ^{14}C incorporation in biological systems. *Nucl. Instr. and Meth. B* **268**, 1295–1298 (2010).
4. Kerpel, S., Shafir, E. & Shapiro, B. Mechanism of fatty acid assimilation in adipose tissue. *Biochimica et Biophysica Acta* **46**, 495–504 (1961).
5. Ekstedt, B. & Olivecrona, T. Uptake and release of fatty acids by rat adipose tissue: Last in–First out? *Lipids* **5**, 858–860 (1970).



Supp. 1, Fig. 3. Non-adipocyte pool. (*Left panel*) Average lipid age as a function of the ratio between of pool 2 and pool 1 sizes (r_2). The average ages given by the two-compartment model (*grey solid lines*) are well approximated by equation (13) (*blue dashed lines*), for small values of r_2 . (*Right panel*) Turnover rates calculated with two-compartment model (*grey solid lines*) and with the approximation (*blue dashed lines*), turnover defined as the inverse of $\langle a \rangle_1$ given by equation (13)). In both panels, pairs of curves were drawn using one set of parameters amongst $k_o^1 = 0.575$, $k_o^2 = k_o^1 f_i$, $k_{12} = f_j$, $k_{21} = f_k$, where $f = (0.01, 0.1, 1, 10, 100)$, and (i, j, k) run from 1 to 5 ($n=125$ pairs of curves). For most of the parameter values, the average age is close to $1/k_o^1$ or $1/(k_o^1 + k_{12})$.

Supplement 2: Patient Information and Tissue Processing

Subjects. Adipose tissue biopsy samples from Swedish (Cohort 1) and German subjects (Cohort 2) were used in this study. The influence of clinical parameters, adipocyte lipolysis and the morphology of adipose tissue were determined in Cohort 1. Abdominal subcutaneous adipose tissue was obtained in the morning after an overnight fast from healthy subjects non-obese or obese ($\text{BMI} > \text{kg/m}^2$) and non-obese patients with familial combined hyperlipidemia (FCHL) by biopsy under local anaesthesia (clinical data in Supplementary Table 1). FCHL was diagnosed as we described previously (1) and diagnosis was confirmed by the author ME who is a clinical lipidologist. Two patients were on a fibrate or a statin. The remaining FCHL subjects received no treatment at the time of investigation. All subjects in Cohort 1 were weight stable for at least 6 months prior to examination according to self report. The non-obese healthy subjects and the FCHL patients had never been obese. In this group adipose samples were collected from 1991-2001. BMI and venous plasma levels of insulin, glucose, triglycerides total and HDL cholesterol and apolipoprotein B (apoB) were determined as described (2). Insulin sensitivity was determined indirectly by calculating a so called HOMA index from insulin and glucose values as described (2). Fat mass was directly measured with bioimpedance using GuadScand 4000 (BodyStat Ltd, Isle of Man, British Isles). In Cohort 2 (clinical data in Supplementary Table 2) lipid turnover in large and small adipocytes from the same sample were examined. Subcutaneous abdominal adipose tissue was obtained from cosmetic liposuction on healthy subjects (collected in 2009). ^{14}C analysis was performed on tissue samples from both cohorts.

Ethical permission for all studies was approved by the ethics committee at Karolinska Institutet, Stockholm, Sweden (Cohort 1) and at Technische Universität München, Germany (Cohort 2).

Separation of adipocytes from the same tissue sample according to size

Details of the method are reported (3). In brief, subcutaneous adipose tissue samples (50-100 g wet weight) were obtained at the Munich site and immediately transported to the laboratory. Isolated fat cells were prepared by the Rodbell method (4). Adipose tissue was minced and digested in Krebs-Ringer-phosphate buffer (KRP) containing 100 U/ml collagenase and 4% albumin for 60 min at 37°C in a shaking water bath. The undigested tissue was removed by filtration. The floating adipocytes were washed three times with KRP containing 0.1% albumin and separated into four fractions exactly as described (3). In brief, ten millilitres of the isolated adipocytes were separated into four fractions (small, medium, large, extra large) adipocyte diameters. The cell volume was calculated from the diameter using a described formula (3). Fraction I (smallest) and IV (largest) were stored at -70°C and subsequently sent to Stockholm for lipid extraction and ¹⁴C analysis of lipids.

Determination of adipose tissue morphology

At any level of total body fat adipose tissue may contain many small fat cells (hyperplasia) or few but large fat cells (hypertrophy) as discussed (5). The relationship between mean adipocyte volume and total body fat determines adipocytes morphology and can be used to classify the adipose morphology into hyperplastic or hypertrophic (5). Briefly, the relationship is described by the following equation: $(V = a \times m)/(1+b \times m)$ where V is the average adipocyte volume (pl), m is the amount of body fat (kg), and a and b are variables that can be estimated by fitting the formula to subject data. We used data regarding subcutaneous adipocyte volume and body fat to estimate a to 42.6 pl/kg and b to 0.033 /kg for the total adipose depot. The differences between the observed adipocyte volume and the expected volume (as obtained from the curve fit) at the corresponding level of total body fat

mass was calculated for each subject, who was then classified as being either hyperplastic (negative deviation) or hypertrophic (positive deviation) relative to the estimated average value for body fat. The validity of using total body fat and fat cell volume from a single adipose region for the determination of the morphology values has been discussed in detail (5). The morphology values are normally distributed (5). When positive they indicate hypertrophy and when negative they are indicative of hyperplasia (5). Small values represent a minor degree of either form of morphology and suggestive of mixed phenotype. Large values are indicative of an extreme phenotype. We presently utilized both continuous values and a subdivision into a hyperplasia or a hypertrophy phenotype.

Extraction of lipids from adipose tissue preparations

Samples were stored at -70°C . Some samples consisted of pieces of intact adipose tissue, others were purified adipocytes isolated from fat tissue according to the collagenase procedure of Rodbell (4). Essentially all lipids of adipose tissue are contained in adipocytes and initial methodological experiments revealed that ^{14}C data from fat pieces and isolated adipocytes gave identical results. As such, both sample types were used in this study and total lipids were extracted exactly as described (6). In brief, adipose tissue (30-40 mg) or packed isolated adipocytes (200 μl) were homogenized with the extraction mixture of Dole. Thereafter heptane and distilled water were added and the heptane phase removed. This was repeated four times and the resultant lipid sample was processed for ^{14}C measurements. The Dole procedure does not extract phospholipids and cholesterol but predominantly acylglycerols. Since human adipose tissue contains minute amounts of diacyl- and monoacylglycerols, we considered the extracted lipids as triglycerides in adipose tissue and fat cells.

Studies of adipocytes lipolysis

These experiments were concluded on samples from non-obese and obese in Cohort 1 exactly as described previously (7). Isolated human fat cells were incubated under dilute conditions (2% vol/vol) in an albumin/glucose containing buffer (pH 7.4) for 2 hours at 37°C. At the end of incubation release of glycerol (lipolysis index) was determined. Different agents were added to the medium at the start of incubation. Adenosine deaminase (1 U/ml) was added in order to remove tracers of adenosine which artificially leaks out of isolated fat cells and inhibit the spontaneous (basal) rate of lipolysis (8). Isoprenaline is a synthetic beta-adrenergic receptor selective catecholamine and was added at $10^{-9} - 10^{-5}$ mol/l. Forskolin ($10^{-7} - 10^{-4}$ mol/l) was added in order to stimulate the endogenous production of cyclic AMP (the key mediator of lipolysis) by acting selectively on adenylate cyclase. Dibutyryl cyclic AMP ($10^{-5} - 10^{-3}$ mol/l) is a cyclic AMP analogue that is resistant to phosphodiesterase which is the major enzyme responsible for intracellular degradation of the nucleotide. It was added to activate protein kinase A so that the lipases responsible for hydrolysis of triglycerides to the end products fatty acid and glycerol are activated. The glycerol values at maximum effective concentration of the lipolytic agents were used in each individual experiment to calculate the maximum stimulated rate of lipolysis. In the present experiment the ratio of forskolin/adenosine deaminase induced lipolysis was 4.3 ± 3.1 (mean \pm SD). Corresponding ratios for dibutyryl cyclic AMP and isoprenaline were 4.2 ± 3.5 and 4.8 ± 3.6 , respectively. There is no consensus how to express lipolysis rates (per amount of lipids or per number of fat cells). As discussed extensively and shown in independent cohorts entirely different results are obtained when subjects with different BMIs are investigated, presumably due to a strong influence on lipolysis values by fat cell size (7,9). For several reasons we choose to express glycerol release per lipid weight. First, this expression correlates best with lipase expression

and body fat mass (7,9). Second, the adipocyte parameters measured by the present ^{14}C method were related to amount of fat and not number of fat cells.

Accelerator mass spectrometry (AMS) measurements

Carbon isotope ratio measurements using AMS require production of negative ions. The sputter ion source injecting the accelerator necessitates the samples to be in graphite form which provides high and stable ion currents. The samples consequently undergo a preparation procedure prior to the AMS analysis, including two chemical processes: 1) Combustion, where the sample is oxidized into CO_2 gas and 2) Graphitization, where the CO_2 gas is reduced into graphite. All laboratory routines comply with the aim of minimizing the amount of background carbon. This includes pre-heating all glassware including borosilicate and quartz vials, as well as the oxidizing agent, the reducing agent and the catalyst for about 3 hours. The temperature used depends on the material but is in the range of 300-900 °C. For a general description of the setup see reference (10).

The samples are placed in a quartz tube with 80 mg of CuO ($\leq 0.002\%$ carbon) and vacuum pumped for about an hour to a vacuum of $< 5 \cdot 10^{-5}$ mbar. The tube is sealed under vacuum with a high temperature torch using liquefied petroleum gas and oxygen. The sealed sample is placed in an oven and baked at 950 °C for 3 hours where the sample is oxidized. The tube containing the CO_2 gas is then moved to a gas transfer setup with a base pressure is in the $2 \cdot 10^{-5}$ mbar range. The tube is punctured and the CO_2 gas is cryogenically transferred and trapped, using liquid nitrogen, into a borosilicate tube containing 100 mg zinc ($< 150\mu\text{m}$ powder, 99.995% pure) as the reducing agent and 2 mg iron powder (325 mesh, 99.9% pure) as the catalyst. Prior to this, any water in the sample is removed using a mixture of ethanol and liquid nitrogen (-80 °C) and any residual gases are pumped away. A small fraction of the sample is used for off-line $^{13}\text{C}/^{12}\text{C}$ ($\Delta^{13}\text{C}$) measurements in an Isotope Ratio Mass

Spectrometer where fractionation of carbon 13 in the samples is measured relative to a standard sample to allow a fractionation correction of the AMS results (11). The $\Delta^{13}\text{C}$ -variation for the samples in this study was typically in the 1 per mil range (variance 0.5‰) which is smaller than the error in the AMS measurements. The sample amount is measured by the pressure of the CO_2 gas in a calibrated volume using a capacitance manometer. The samples were typically in the range corresponding to 200-900 μg carbon. The vial containing the CO_2 sample gas is subsequently heated to 550 °C for 6 hours. The produced graphite is pressed into an aluminium cathode which is then loaded into the ion source of the accelerator at the Uppsala University, Tandem Accelerator Laboratory. The AMS analysis uses 12 MeV carbon ions, where the ^{12}C current is measured using a faraday cup and the ^{14}C ions are detected individually, using a solid state detector where the energy spectrum of the incoming ion is concurrently analyzed for unambiguous identification and detection. The samples are analyzed four times, each acquisition period lasting 300 seconds. This is complemented with data acquired from 3 separate NIST traced standards (Oxalic Acid II) to ensure correct normalization. Data is presented as Fraction Modern, $F^{14}\text{C}$, which is the preferred unit for representing isotopic ratio in this application. It is defined as the ratio of the ^{14}C to ^{12}C carbon for a sample divided by that of a well defined standard sample, measured in the same year and incorporating ^{13}C fractionation correction (See reference 12). Fractionation variations in the graphitization process were measured to be below 0.1%. This was done by re-combusting the graphitized samples and analysing them using Stable Isotope Ratio Mass Spectrometry.

Statistical Methods

Values are, unless otherwise stated, mean \pm standard error of mean in figures and mean \pm standard deviation in tables. They were compared using paired or unpaired t-test, analysis of variance (ANOVA), analysis of covariance (ANCOVA) and linear or multiple regression

analysis. Values for HOM index, plasma triglycerides and lipid storage (K_{in}) were 10 log transformed in order to normalize distribution. Since no previous information existed in adipose lipid age from atmospheric ^{14}C data we used published short-term experimental data on triglyceride turnover in human adipose tissue obtained from 18 men (13). Standard deviation divided by mean value was 0.5. We tested between group differences in lipid age which could be detected with an unpaired or paired t-test at $p < 0.05$ with 80% power. In Cohort 1 (2-3 groups) we could detect a difference of 15-25 % between any group combination with unpaired t-test. In Cohort 2 (2 groups) we could detect a difference of 20-30% with paired t-test.

References Supplement 2

1. Reynisdottir, S., Eriksson, M., Angelin, B., Arner P. Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia. *J Clin Invest* 95:2161-2169 (1995)
2. Wahrenberg, H., Hertel, K., Leijonhufvud, B.M., Persson, L.G., Toft, E., Arner, P. Use of waist circumference to predict insulin resistance: retrospective study. *BMJ* 330:1363-1364,(2005).
3. Skurk, T., Alberti-Huber, C., Herder, C., Hauner, H. Relationship between adipocyte size and adipokine expression and secretion. *J Clin Endocrinol Metab* 92: 1023-33 (2007).
4. Rodbell, M. Metabolism of Isolated Fat Cells. I. Effects of hormones on glucose Metabolism and Lipolysis. *J Biol Chem* 239: 375-380 (1964).
5. Arner, E., Westermark, P. O., Spalding, K. L., et al. Adipocyte turnover: relevance to human adipose tissue morphology. *Diabetes* 59: 105-109 (2010).

6. Arner, P., Östman, J. Mono- and diacylglycerols in human adipose tissue. *J Biol Chem* 242: 4845-4849 (1967).
7. Large, V., Reynisdottir, S., Langin, D., Fredby, K., Klannemark, M., Holm, C., Arner, P. Decreased expression and function of adipocyte hormone-sensitive lipase in subcutaneous fat cells of obese subjects. *J Lipid Res* 40:2059-2066, (1999).
8. Kather, H. Pathways of purine metabolism in human adipocytes. Further evidence against a role of adenosine as an endogenous regulator of human fat cell function. *J Biol Chem* 265:96-102,(1990).
9. Langin, D., Dicker, A., Tavernier, G., Hoffstedt, J., Marial, A., Rydén, M., Arner, E., Sicard, A., Jenkins, C.M., Viguerie, N., Harmelen, V., Gross, R.W., Holm, C., Arner, P. Adipocyte lipases and defect of lipolysis in human obesity. *Diabetes* 54:3190-3197, (2005).
10. Salehpour, M., Forsgard, N., Possnert, G. FemtoMolar measurements using accelerator mass spectrometry. *Rapid Commun Mass Spectrom.* 23:557-63 (2009).
11. Stuiver, M., Polach, H.A. Discussion: reporting of ¹⁴C data. *Radiocarbon* 19: 355-363, (1977).
12. Reimer, P. J., Brown, T. A., Reimer, R. W. Discussion: reporting and calibration of ¹⁴C data *Radiocarbon* 46:129-1304 (2004).
13. Strawford, A., Antelo, F., Christiansen, M. & Hellerstein, M. K. Adipose tissue triglyceride turnover, de novo lipogenesis, and cell proliferation in humans measured with ²H₂O. *Am J Physiol Endocrinol Metab* 286, E577-88 (2004).